Pediatricians’ attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey

OBJECTIVE: Nirsevimab and the maternal vaccination in pregnancy are newly introduced prevention strategies against respiratory syncytial virus (RSV). This study evaluated pediatricians' knowledge, attitudes, and barriers to RSV immunization in Italy and Cyprus/Greece, where nirsevimab had not yet been implemented, and in Spain, where it was introduced in 2023/2024. METHODS: A survey was distributed to pediatricians across Spain, Italy, and Cyprus/Greece in July-August/2024. Occupational characteristics, and knowledge, attitudes and practices toward palivizumab, nirsevimab, and the maternal vaccine were collected. Of 578 respondents (response rate = 19.3%), 50% were from Spain, 40% from Italy, and 10% from Cyprus/Greece. As 90% of responses came from Spain and Italy, the main analysis focused on these two countries. Descriptive and univariate analyses (Chi-square or Fisher's exact tests) were conducted. RESULTS: Respondents included pediatricians from community (51.7%), tertiary (30.4%), and primary/secondary care (17.9%) settings. Pediatricians were generally aware of RSV risk factors, without differences across countries. However, 245 (55.9%) and 375 (86.0%) participants reported average-to-low knowledge of nirsevimab and the maternal vaccine, respectively, with differences across countries (p = 0.002). Despite limited knowledge, 311 (85.9%) pediatricians were willing to administer nirsevimab, and 319 (92.2%) supported its use for all infants. Nirsevimab administration's barriers, including unfamiliarity and logistical challenges, were cited by 69 (20.0%) pediatricians. Regarding immunization preferences, 165 (47.4%) pediatricians were very likely to support the maternal vaccine over nirsevimab. CONCLUSIONS: While pediatricians support RSV immunization, knowledge gaps and logistical barriers may hinder early-stage implementation. Optimizing education on RSV immunization will be crucial to improve uptake and prevention strategies.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-08-17
DOI
https://doi.org/10.1371/journal.pone.0356233
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pediatricians’ attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey

Luigi Cantarutti, Shaun K. Morris, Zoi Dorothea Pana, A. G. Rose et al.
PLoS ONE
Respiratory viral infections research
article

Pediatricians’ attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey

Luigi Cantarutti, Shaun K. Morris, Zoi Dorothea Pana, A. G. Rose, Daniele Donà, Vera Rigamonti, Antoni Soriano‐Arandes, Carlo Giaquinto, Anna Cantarutti, Cristina Calvo, Costanza Di Chiara, Alfredo Tagarro, Irene Rivero‐Calle, Andrea Lo Vecchio, Ioannis Kopsidas, Pierre-Philippe Piché-Renaud, Adamos Hadjipanayis
article en

Abstract

OBJECTIVE: Nirsevimab and the maternal vaccination in pregnancy are newly introduced prevention strategies against respiratory syncytial virus (RSV). This study evaluated pediatricians' knowledge, attitudes, and barriers to RSV immunization in Italy and Cyprus/Greece, where nirsevimab had not yet been implemented, and in Spain, where it was introduced in 2023/2024. METHODS: A survey was distributed to pediatricians across Spain, Italy, and Cyprus/Greece in July-August/2024. Occupational characteristics, and knowledge, attitudes and practices toward palivizumab, nirsevimab, and the maternal vaccine were collected. Of 578 respondents (response rate = 19.3%), 50% were from Spain, 40% from Italy, and 10% from Cyprus/Greece. As 90% of responses came from Spain and Italy, the main analysis focused on these two countries. Descriptive and univariate analyses (Chi-square or Fisher's exact tests) were conducted. RESULTS: Respondents included pediatricians from community (51.7%), tertiary (30.4%), and primary/secondary care (17.9%) settings. Pediatricians were generally aware of RSV risk factors, without differences across countries. However, 245 (55.9%) and 375 (86.0%) participants reported average-to-low knowledge of nirsevimab and the maternal vaccine, respectively, with differences across countries (p = 0.002). Despite limited knowledge, 311 (85.9%) pediatricians were willing to administer nirsevimab, and 319 (92.2%) supported its use for all infants. Nirsevimab administration's barriers, including unfamiliarity and logistical challenges, were cited by 69 (20.0%) pediatricians. Regarding immunization preferences, 165 (47.4%) pediatricians were very likely to support the maternal vaccine over nirsevimab. CONCLUSIONS: While pediatricians support RSV immunization, knowledge gaps and logistical barriers may hinder early-stage implementation. Optimizing education on RSV immunization will be crucial to improve uptake and prevention strategies.

PLoS ONEVol. 21(8)
University of Padua (IT), University of Toronto (CA), National and Kapodistrian University of Athens (GR), European University Cyprus (CY), Hospital Universitario La Paz (ES), Hospital for Sick Children (CA), Instituto de Salud Carlos III (ES), University of Cyprus (CY), Research Institute Hospital 12 de Octubre (ES), Centro de Investigación en Red en Enfermedades Cardiovasculares (ES), Complejo Hospitalario Universitario de Santiago (ES), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES), Vall d'Hebron Institut de Recerca (ES), Hospital La Paz Institute for Health Research (ES), Spanish Clinical Research Network (ES), Federico II University Hospital (IT), Informatica Tecnologie e Servizi (Italy) (IT), Public Health Ontario (CA), SickKids Foundation (CA), Institute for Clinical Evaluative Sciences (CA), Instituto de Investigación Sanitaria de Santiago (ES), Hospital Universitario Infanta Sofía (ES), Hospital de Palamós (ES), University of Milano-Bicocca (IT), University of Naples Federico II (IT), Universidad Europea de Madrid (ES)
Good health and well-being
Openalex Percentile: Top 9%
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.